Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
1 finding from 1 review
Serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).
1 finding from 1 review
Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · people with multifocal motor neuropathy
1 finding from 1 review
Serious adverse events · people with fatigue in peripheral neuropathy
Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
80 participants
GRADE not reported
Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.6, 1.3]
1586 participants
Moderate
Intervention not reported
Serious adverse events · painful diabetic neuropathy
1 finding from 1 review
no estimate extracted
1304 participants
Moderate
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAE; %) · adults with CMT1A
1 finding from 1 review
Serious or severe adverse events · people with diabetes and orthostatic hypotension
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Adverse events/serious adverse events · people with NMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events/serious adverse events · people with NMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found